Summit Therapeutics PLC (SMMT NASDAQ) stock market data APIs
$16.9418
0.87(5.1%)
as of November 17, 2025
Try our APIs with
free plan!
Summit Therapeutics PLC Financial Data Overview
Price chart is built with
Anychart
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis, as well as in Phase III clinical trials for the treatment of non-small lung cancer. The company was founded in 2003 and is headquartered in Miami, Florida.
Prev. Close
16.9418
Open
17.8165
High
17.8393
Low
16.8009
52 wk Range
15.55-36.91
Market Cap
12 618 M
Shares Outstanding
744 M
EPS
-0.2315
Beta
-1.547
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Summit Therapeutics PLC (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Summit Therapeutics PLC data using free add-ons & libraries
Get Summit Therapeutics PLC Fundamental Data
Summit Therapeutics PLC Fundamental data includes:
- Net Revenue:
- EBITDA: -934 987 008
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-10-28
- EPS/Forecast: -0.1032
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Summit Therapeutics PLC News
New
MRK Up Nearly 10% in a Month: Should You Buy, Sell or Hold the Stock?
Merck’s MRK shares have risen 9.6% in a month. The company’s stock declined after it announced third-quarter results. Though it beat estimates for both earnings and sales, its blockbuster PD-L1 in...
Summit Therapeutics (SMMT) Reports Positive Results from the Phase III HARMONi Trial
Summit Therapeutics Inc. (NASDAQ:SMMT) is one of the 15 stocks set to explode in 2026.Summit Therapeutics (SMMT) Reports Positive Results from the Phase III HARMONi Trial On November 7, 2025, Summit ...
Will Keytruda Aid MRK's Growth in 2026 After a Subdued Q3?
Merck’s MRK strong position in the oncology market is largely driven by its biggest revenue driver, Keytruda. The blockbuster PD-L1 inhibitor contributes over half of the company’s pharmaceutical ...
Friday Sector Laggards: Semiconductors, Biotechnology Stocks
In trading on Friday, semiconductors shares were relative laggards, down on the day by about 3%. Helping drag down the group were shares of Ambarella off about 17.3% and shares of Wolfspeed off about...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
